MedTrace Logo

Atrial Pacing for Termination and Prevention of Atrial Fibrillation

NCT00123344 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2008-12-11

No results posted yet for this study

Summary

Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with substantial morbidity and mortality. Present treatment strategies are aimed at termination of AF and prevention of AF recurrence using antiarrhythmic drugs or heart rate control drugs. Drugs are not always well tolerated, so atrial pacing as a strategy for prevention of atrial tachyarrhythmias is being explored.

The AT501 pacemaker has both "prevention" and "treatment" algorithms for atrial tachyarrhythmias. The investigators wish to determine whether these special features, over the long term, decrease the amount of time the person experiences AF.

Conditions

Interventions

DEVICE

AT501 pacemaker

Sponsors & Collaborators

  • Heart and Stroke Foundation of Ontario

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Anne M Gillis, MD · University of Calgary, Professor of Medicine

  • D. George Wyse, MD, Ph.D · University of Calgary, Professor of Medicine

  • John M Rothschild, MD · University of Calgary, Professor of Medicine

  • M Sarah Rose, Ph D · University of Calgary, Statistician

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-12-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00123344 on ClinicalTrials.gov